Si‐Yang Liu

Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial

Qun Wang, Weimin Mao, Lin Wu et al. · Journal of Clinical Oncology · 2020 · 279 citations · Full text

Medicine, Oncology, Pharmacology +15

Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non–Small Cell Lung Cancer

Jia‐Tao Zhang, Si‐Yang Liu, Wei Gao et al. · Cancer Discovery · 2022 · 222 citations · Full text

Medicine, Clinical Sciences, Oncology +17

Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients

Yi Pan, Jia‐Tao Zhang, Xuan Gao et al. · Cancer Cell · 2023 · 93 citations

Medicine, Cancer Biology, Oncology +14

Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial

Wen‐Zhao Zhong, Hong‐Hong Yan, Ke‐Neng Chen et al. · Signal Transduction and Targeted Therapy · 2023 · 77 citations · Full text

Medicine, Oncology, Pharmacology +14

Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes

Si‐Yang Liu, Hua Bao, Qun Wang et al. · Nature Communications · 2021 · 75 citations · Full text

Medicine, Molecular Genetics, Oncology +15